Cingulate Inc
CING5.203USD
+0.103+2.03%
시장 운영 시간 （ET）시세는 15분 지연됩니다
19.91M시가총액
손실P/E TTM
자세한 내용은 Cingulate Inc 회사
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
회사 정보
종목 코드 CING
회사 이름Cingulate Inc
상장일Oct 07, 2021
CEODr. Shane J. Schaffer, Pharm.D.
직원 수13
유형Ordinary Share
회계 연도 종료Oct 07
주소1901 W. 47Th Place
도시KANSAS CITY
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호66205
전화19139422300
웹사이트https://www.cingulate.com/
종목 코드 CING
상장일Oct 07, 2021
CEODr. Shane J. Schaffer, Pharm.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Matthew N. Brams, M.D.
Dr. Matthew N. Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Dr. Shane J. Schaffer, Pharm.D.
Dr. Shane J. Schaffer, Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Independent Director
Independent Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
--
--
Dr. Laurie A. Myers, Ph.D.
Dr. Laurie A. Myers, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Matthew N. Brams, M.D.
Dr. Matthew N. Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Dr. Shane J. Schaffer, Pharm.D.
Dr. Shane J. Schaffer, Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Independent Director
Independent Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Wed, Jul 2
마지막 업데이트: Wed, Jul 2
주주
주주 유형
주주
주주
비율
Werth Family Investment Associates LLC
1.90%
Commonwealth Financial Network
1.08%
Geode Capital Management, L.L.C.
0.59%
UBS Financial Services, Inc.
0.43%
The Vanguard Group, Inc.
0.21%
Other
95.79%
주주
주주
비율
Werth Family Investment Associates LLC
1.90%
Commonwealth Financial Network
1.08%
Geode Capital Management, L.L.C.
0.59%
UBS Financial Services, Inc.
0.43%
The Vanguard Group, Inc.
0.21%
Other
95.79%
주주 유형
주주
비율
Investment Advisor
2.37%
Corporation
2.32%
Investment Advisor/Hedge Fund
0.70%
Research Firm
0.05%
Individual Investor
0.01%
Other
94.55%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
44
238.41K
5.46%
-49.05K
2025Q1
47
242.60K
6.03%
-49.04K
2024Q4
47
197.43K
6.15%
-35.64K
2024Q3
47
156.73K
4.97%
-40.96K
2024Q2
44
186.43K
34.55%
+67.80K
2024Q1
47
54.28K
18.74%
+25.73K
2023Q4
45
21.28K
29.79%
-7.47K
2023Q3
42
26.64K
41.94%
+1.78K
2023Q2
36
15.08K
30.98%
-2.19K
2023Q1
34
15.09K
32.03%
-921.00
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Werth Family Investment Associates LLC
97.99K
2.31%
--
--
Apr 14, 2025
Commonwealth Financial Network
55.52K
1.31%
+12.50K
+29.05%
Mar 31, 2025
Geode Capital Management, L.L.C.
30.40K
0.72%
+3.08K
+11.26%
Mar 31, 2025
UBS Financial Services, Inc.
22.12K
0.52%
+9.92K
+81.34%
Mar 31, 2025
The Vanguard Group, Inc.
10.76K
0.25%
+8.76K
+438.54%
Mar 31, 2025
Quantum Private Wealth, LLC
10.00K
0.24%
+10.00K
--
Mar 31, 2025
Alphamark Advisors, LLC
5.01K
0.12%
+5.00K
+50000.00%
Dec 31, 2024
Fountainhead Shrugged, LLC
3.37K
0.08%
--
--
Apr 14, 2025
BofA Global Research (US)
1.96K
0.05%
+2.00
+0.10%
Mar 31, 2025
Tower Research Capital LLC
433.00
0.01%
-331.00
-43.32%
Mar 31, 2025
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Nov 28, 2023
Merger
20<1
Nov 28, 2023
Merger
20<1
날짜
유형
비율
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Nov 28, 2023
Merger
20<1
Nov 28, 2023
Merger
20<1
Nov 28, 2023
Merger
20<1
Nov 28, 2023
Merger
20<1
